{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:19:03Z","timestamp":1792084743646,"version":"4.4.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a well-recognized autoimmune condition that often presents with neuropsychiatric symptoms and seizures. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) often manifests as optic neuritis and, less frequently, as acute demyelinating encephalomyelitis or transverse myelitis. The co-occurrence of anti-NMDAR encephalitis and MOGAD is becoming increasingly recognized, but clinical series remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Description of cases<\/jats:title>\n                    <jats:p>We present three patients with anti-NMDAR encephalitis and MOGAD optic neuritis (ON): two men, aged 19 and 26, and one woman, aged 36. Clinical presentations, signs, investigations, and management of each case are discussed. The 26-year-old man presented with altered mental status and concurrent vision loss. The 36-year-old woman presented with altered mental status during the encephalitis episode and developed vision loss 4\u202fmonths after encephalitis. The 19-year-old man with a prior history of altered mental status, diagnosed with NMDA encephalitis 9\u202fyears earlier, presented with headache and vision loss. Abnormal T2\/FLAIR lesions in the brain and\/or spinal cord during the encephalitis episode and unilateral or bilateral optic nerve enhancement during the optic neuritis episode were detected on brain and orbital magnetic resonance imaging (MRI) in all patients. All patients tested positive for cerebrospinal fluid (CSF) anti-NMDAR antibodies during the encephalitis episode and had positive serum MOG titers during the optic neuritis episode. Each patient presented with bilateral, asymmetrically reduced visual acuity and diminished color vision. One patient exhibited bilateral temporal optic nerve pallor, while two patients had bilateral optic nerve edema. The diagnostic work-up revealed positive serum MOG titers (1:100, 1:10,000, and 1:10,000 in the 36\/F, 26\/M, and 19\/M, respectively). The 36-year-old woman was treated with intravenous (IV) steroids, plasma exchange (PLEX), and rituximab during the encephalitis episode. During the optic neuritis episode, she was treated with IV steroids, IV immunoglobulin (IVIG), and rituximab, followed by long-term rituximab maintenance therapy. The 19-year-old man was treated for encephalitis with IV steroids, IVIG, and rituximab. During his optic neuritis episode, he received IV steroids, IVIG, and tocilizumab, followed by long-term tocilizumab maintenance therapy. The 26-year-old man was treated with IV steroids, PLEX, and rituximab during the acute episode, followed by long-term IVIG maintenance therapy. After achieving 2\u202fyears of stability that prompted the discontinuation of IVIG, the patient experienced a MOG-IgG-positive relapse 5\u202fmonths later. This relapse was marked by a seizure-like episode and the appearance of new lesions on MRI. The acute symptoms resolved after treatment with intravenous steroids and IVIG. Subsequently, the patient was initiated on an indefinite maintenance IVIG regimen. Visual acuity in all patients improved to their baseline levels following treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This series highlights the emerging overlap between anti-NMDAR encephalitis and MOGAD optic neuritis. Optic neuritis may occur months to years after encephalitis, underscoring the need for careful monitoring of patients with anti-NMDAR encephalitis who develop new visual symptoms. Dual autoimmunity may represent a distinct phenotype with implications for long-term immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1869098","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:25:36Z","timestamp":1783657536000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-NMDA-receptor encephalitis and MOGAD associated optic neuritis: a case series"],"prefix":"10.3389","volume":"17","author":[{"given":"Pooja","family":"Parthasarathi","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Emory University","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dattilo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Emory University","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Peragallo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Emory University","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1016\/j.neuron.2023.05.002","article-title":"NMDA receptor functions in health and disease: old actor, new dimensions","volume":"111","author":"Dupuis","year":"2023","journal-title":"Neuron"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ana.20614","article-title":"Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma","volume":"58","author":"Vitaliani","year":"2005","journal-title":"Ann Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ana.21050","article-title":"Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma","volume":"61","author":"Dalmau","year":"2007","journal-title":"Ann Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(19)30244-3","article-title":"An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models","volume":"18","author":"Dalmau","year":"2019","journal-title":"Lancet Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e200255","DOI":"10.1212\/NXI.0000000000200255","article-title":"Racial and ethnic disparities in the incidence of anti-NMDA receptor encephalitis","volume":"11","author":"Alsalek","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3389\/fimmu.2017.00529","article-title":"Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases","volume":"8","author":"Peschl","year":"2017","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O\u2019Connor","year":"2007","journal-title":"Nat Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J Neuroinflammation"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1474-4422(22)00187-9","article-title":"Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment","volume":"22","author":"Bennett","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s00415-024-12861-9","article-title":"MOG antibody-associated disease epidemiology in Olmsted County, USA, and Martinique","volume":"272","author":"Cacciaguerra","year":"2025","journal-title":"J Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ana.24117","article-title":"Overlapping demyelinating syndromes and anti\u2013N-methyl-D-aspartate receptor encephalitis","volume":"75","author":"Titulaer","year":"2014","journal-title":"Ann Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12974-016-0678-4","article-title":"Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous system","volume":"13","author":"Sinmaz","year":"2016","journal-title":"J Neuroinflammation"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2517813","DOI":"10.1080\/07853890.2025.2517813","article-title":"The spectrum of overlapping anti-NMDAR encephalitis and demyelinating syndromes: a systematic review of presentation, diagnosis, management, and outcomes","volume":"57","author":"Saeed","year":"2025","journal-title":"Ann Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s00415-025-13011-5","article-title":"Clinical characterization of diseases associated with anti-N-methyl-D-aspartate receptor encephalitis combined with anti-myelin oligodendrocyte glycoprotein antibodies in adults","volume":"272","author":"Ding","year":"2025","journal-title":"J Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1664666","DOI":"10.3389\/fimmu.2025.1664666","article-title":"Clinical features and prognosis of the adult patients positive for both N-methyl-d-aspartate receptor and myelin oligodendrocyte glycoprotein antibodies","volume":"16","author":"Ma","year":"2025","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jneuroim.2018.12.003","article-title":"A case of recurrent MOG antibody positive bilateral optic neuritis and anti-NMDAR encephalitis: different biological evolution of the two associated antibodies","volume":"328","author":"Rojc","year":"2019","journal-title":"J Neuroimmunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3389\/fneur.2019.01271","article-title":"Co-occurrence of anti-N-methyl-D-aspartate receptor encephalitis and anti-myelin oligodendrocyte glycoprotein inflammatory demyelinating diseases: a clinical phenomenon to be taken seriously","volume":"10","author":"Ren","year":"2019","journal-title":"Front Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"857443","DOI":"10.3389\/fimmu.2022.857443","article-title":"Clinical characteristics of anti-N-methyl-d-aspartate receptor encephalitis overlapping with demyelinating diseases: a review","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"799454","DOI":"10.3389\/fimmu.2022.799454","article-title":"Case report: overlapping syndrome of anti-NMDAR encephalitis and MOG inflammatory demyelinating disease in a patient with human herpesviruses 7 infection","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1694771","DOI":"10.3389\/fimmu.2026.1694771","article-title":"Case report: overlap syndrome of anti-NMDA receptor encephalitis and MOG-associated disease in a pediatric patient-literature insights","volume":"17","author":"Krir","year":"2026","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.1007\/s10072-024-07474-z","article-title":"Clinical features of adult patients with positive NMDAR-IgG coexisting with MOG-IgG","volume":"45","author":"Dai","year":"2024","journal-title":"Neurol Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamaneurol.2021.3188","article-title":"Use and safety of immunotherapeutic management of N-methyl-d-aspartate receptor antibody encephalitis: a Meta-analysis","volume":"78","author":"Nosadini","year":"2021","journal-title":"JAMA Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jamaneurol.2024.2811","article-title":"Time to treat first acute attack of myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"81","author":"Kwon","year":"2024","journal-title":"JAMA Neurol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/jnnp-2022-330360","article-title":"Time to steroids impacts visual outcome of optic neuritis in MOGAD","volume":"94","author":"Rode","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1869098\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:25:37Z","timestamp":1783657537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1869098\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":26,"alternative-id":["10.3389\/fneur.2026.1869098"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1869098","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"1869098"}}